The initiative also would have authorized state-licensed "psychedelic therapy centers." ...
FDA granted approvals for Bristol Myers Squibb's Cobenfy (formerly KarXT) for schizophrenia, Johnson and Johnson's Tremfya for ulcerative colitis and Servier's Voranigo for IDH-mutant glioma, a type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback